Navigation Links
Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
Date:11/19/2007

SAN DIEGO, Nov. 19 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Jorgine Ellerbrock has joined the Company as senior vice president, operations.

"We are pleased to add Jorgine's extensive experience in operations and supply chain management to our already strong senior management team," said Carl Hull, Gen-Probe's executive vice president and chief operating officer.

Ms. Ellerbrock, 46, joins the Company from Invitrogen Corporation, where she had been vice president, operations, since 2004, most recently for the Molecular Biology Business. Prior to joining Invitrogen, she held positions of increasing responsibility with GE Healthcare Bio-Sciences (formerly Amersham Biosciences). She served as vice president, operations from 2002 to 2004, and vice president, genomics product management, in 2002. Before joining Amersham in 1998, Ms. Ellerbrock was employed by Roche Molecular Systems and Gen-Probe. She earned a BS in microbiology and an MBA from San Diego State University.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include, but are not limited to, the risk that we cannot retain key executives. The foregoing sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Senior director, investor relations and corporate communications

858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
4. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
5. Nick Childs Joins Grey New York as Director of Content Development
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
8. NASN Joins Partnership to Fight Chronic Disease
9. AstraZeneca Joins Local Walking Movement
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Fund Manager Joins Board of GSI Securitization Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce that ... Mr. Still was selected through a careful months-long search by the RBMA Board of ... our members, has been a part of building the RBMA since 1992,” said RBMA ...
(Date:3/28/2017)... Conn. (PRWEB) , ... March 28, 2017 , ... ... based in Wethersfield, Conn., has relocated its corporate headquarters to a new, more ... clients. , In October 2016, Qualidigm purchased a distressed office building in ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process ... in power plant water and steam. , Chlorides and sulfates cause pitting and ... to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... DIEGO and VANCOUVER, British Columbia, March 27, 2017 ... ) (the "Company" or "Sophiris"), a clinical late-stage ... of patients with urological diseases, today reported fourth ... key corporate highlights. Key Corporate ... Clinical Development for Localized Prostate Cancer. During 2016, ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... -- The staggering cost of cancer treatment means only ... the latest treatment options against cancer. Even among the ... inadequate or no health insurance and are oftentimes saddled ... modern cancer treatment is almost non-existent for cancer patients ... mission statements of pharmaceutical and biotech companies often quote ...
Breaking Medicine Technology: